Shenzhen Hepalink Pharmaceutical Group

Resverlogix Corp. is a late-stage clinical biotechnology company based in Calgary, Canada, focused on developing innovative therapeutics for cardiovascular diseases and related conditions. The company's lead product, apabetalone, is a first-in-class small molecule that selectively inhibits the bromodomain and extra-terminal (BET) proteins, targeting the second bromodomain to influence disease-causing genes. Apabetalone is currently undergoing Phase III clinical trials for various indications, including cardiovascular disease, chronic kidney disease, and neurodegenerative disorders. In addition to apabetalone, Resverlogix is advancing several development programs, including NexVas technologies aimed at plaque regression and vascular inflammation, as well as therapeutic candidates for Alzheimer's disease and fibrotic conditions. The company's research underscores its commitment to addressing significant unmet medical needs through innovative biopharmaceutical solutions.

OncoQuest Inc. is a biotechnology company based in Edmonton, Canada, founded in 2015. As a subsidiary of Quest PharmaTech, Inc., OncoQuest focuses on developing immunotherapeutic products aimed at treating cancer. The company has assembled a portfolio of bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE classes, which are designed to induce tumor-specific immunity. With several lead components backed by clinical track records and extensive development dossiers, OncoQuest aims to integrate these therapies into combinatorial immuno-oncology treatment strategies. By exploring the therapeutic potential of antibodies in conjunction with other immune-modulating drugs, OncoQuest seeks to enhance clinical outcomes for cancer patients.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

Shanghai Labway Clinical Laboratory Co., Ltd. is a prominent provider of medical laboratory services based in Shanghai, China, established in 1993. The company specializes in in vitro diagnostic products and offers a range of comprehensive health management solutions, including genetic testing, clinical microbiology testing, blood and pathology testing, and cytopathological diagnosis. Labway focuses on optimizing resource allocation for healthcare institutions, aiming to reduce costs and risks while enhancing efficiency and patient satisfaction. Through its services, Labway plays a significant role in promoting effective public healthcare management.

OncoQuest Inc. is a biotechnology company based in Edmonton, Canada, founded in 2015. As a subsidiary of Quest PharmaTech, Inc., OncoQuest focuses on developing immunotherapeutic products aimed at treating cancer. The company has assembled a portfolio of bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE classes, which are designed to induce tumor-specific immunity. With several lead components backed by clinical track records and extensive development dossiers, OncoQuest aims to integrate these therapies into combinatorial immuno-oncology treatment strategies. By exploring the therapeutic potential of antibodies in conjunction with other immune-modulating drugs, OncoQuest seeks to enhance clinical outcomes for cancer patients.

Cytovance Biologics, Inc. is a biopharmaceutical contract manufacturing organization based in Oklahoma City, specializing in the production of therapeutic proteins and antibodies through mammalian cell culture and microbial fermentation. Founded in 2003, the company offers a comprehensive range of services including cell line selection, process development, purification, fill/finish operations, and cGMP manufacturing. Cytovance also provides analytical development, quality assurance, and regulatory support services to ensure compliance with industry standards. Its state-of-the-art facilities are FDA inspected, enabling the company to cater to biopharmaceutical clients across the United States. As a subsidiary of Hepalink USA Inc., Cytovance is committed to delivering innovative manufacturing solutions and support for the development and commercialization of large molecule active pharmaceutical ingredients.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Scientific Protein Laboratories LLC engages in manufacturing active pharmaceutical ingredients (APIs) for pharmaceutical, veterinary, and food industries worldwide. It offers heparin products, pancreatic enzyme products, derivative, blends, and custom specifications. The company also provides contract biopharmaceutical development and manufacturing services, including natural products extraction, fermentation and purification, analytical support, and heparin derivatives production. In addition, it supports its clients in various aspects of regulatory compliance, including providing CMC sections of IND, NDA, and aNDA; and offers process validation and equipment qualification services in support of its customers’ regulatory filings. The company was founded in 1976 and is based in Waunakee, Wisconsin.